Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month
Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.
How this was made
The 30-second read
Why it matters
The extended Phase 3 Optima data reduces the probability of new lesion formation during weeks 56 to 84 for Pasatru-treated patients, strengthening the durability case after FDA approval. It also sets expectations for the upcoming pediatric Phase 3 (Optima 2) and may support the ongoing European regulatory review.
Market read
Traders can use the extended lesion durability data to reassess near-term sentiment and risk around Pasatru’s post-approval trajectory, while waiting for pediatric results and European regulatory updates.
What to watch
The article does not quantify safety signals in the extended window, and it does not provide effect size beyond lesion counts; Optima 2 in children and ongoing European review remain key swing factors.
Background
Pasatru (Regeneron) is a recently approved treatment for fibrodysplasia ossificans progressiva (FOP), targeting Activin A to prevent abnormal bone formation.
Ticker impact
Regeneron reported Optima Phase 3 results showing zero new abnormal bone lesions between weeks 56 and 84 on Pasatru versus nine on placebo.
Likely near-term support as traders price in durability of Pasatru’s benefit and reduced risk of new lesion formation in the extended window.
The article provides specific extended-trial lesion outcomes and notes FDA approval plus planned pediatric Phase 3, which are direct catalysts for sentiment. However, it is not a new regulatory decision or a fresh FDA label change, limiting magnitude.
Market effects
Reinforces confidence in rare-disease biotech durability of mechanism-targeted therapies, potentially supporting sentiment across the biotech complex.
Primarily US biotech sentiment, with limited direct regional spillover beyond healthcare/biotech risk appetite.
European regulators are reviewing Pasatru, so durable efficacy data can influence broader global rare-disease expectations.
Counterpoint
Zero new lesions in the extended window may reflect small sample size and trial design; investors could be over-weighting durability before pediatric outcomes and regulator decisions.
Key entities
- companyRegeneron Pharmaceuticals
Reported extended Phase 3 Optima results for Pasatru in FOP, including zero new abnormal bone lesions between weeks 56 and 84.
- drugPasatru
Regeneron’s rare disease drug for FOP, designed to block Activin A involved in abnormal bone formation.
- clinical_trialOptima trial
Phase 3 study in adults receiving Pasatru or placebo every four weeks, with extended follow-up lesion outcomes.
- regulatorFDA
Approved Pasatru in August; European regulators are currently reviewing it.
- conferenceASBMR
Presented the findings at the American Society for Bone and Mineral Research.
